GSK today announced that it has submitted a regulatory application to the European Medicines Agency (EMA) for its antiseptic chlorhexidine gel (7.1% chlorhexidine digluconate gel, equivalent to 4% chlorhexidine) for the prevention of umbilical cord infections (omphalitis) in newborn babies. GSK’s work to develop the gel began in response to a call from the United Nations (UN) in 2012 for manufacturers to make a high quality chlorhexidine product suitable for newborn infants in low resources settings.
If you drive through the City of Detroit, it’s almost a tale of two cities. There’s the city of business growth and revitalization, but there’s also the city of neighborhood blight and decades of decay.
In a recent presentation on “Social Finance and Investing in Carbon Efficiency” at SOCAP 15, Mellon Capital CEO Gabriela Franco Parcella explored how the firm approaches partner and product innovation to meet competing client needs regarding fiduciary duty and environmental objectives.
A group of Indianapolis Colts players teamed up with local Republic Services team members to build a playground to serve over 300 students at Floro Torrence School 83 – Indianapolis Public Schoo
There are so many brilliant minds working to develop innovative solutions to improve conditions all over the world. But what separates the business ideas that are able to make an impact on millions of lives from the ones that may only reach a few hundred people is an ability to scale.
